← Back to Screener
argenx SE American Depositary Shares (ARGX)
Price$891.32
Value ScoreD
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-10.02%
Price vs S&P 500 (4W)10.83%
VGM Score59.30
Market Capitalization$45.10B
P/E Ratio (Annual)40.22x
All Metrics
P/CF (Annual)75.85x
Book Value / Share (Quarterly)$118.34
P/TBV (Annual)7.17x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)116.21%
Cash Flow / Share (Quarterly)$9.27
Price vs S&P 500 (YTD)-0.49%
Gross Margin (TTM)144.51%
Net Profit Margin (TTM)48.24%
EPS (TTM)$34.00
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$34.00
Revenue Growth (5Y)151.52%
EPS (Annual)$19.57
ROI (Annual)17.53%
Gross Margin (Annual)89.14%
Net Profit Margin (5Y Avg)-41.95%
Cash / Share (Quarterly)$71.75
P/E Basic Excl Extra (TTM)23.12x
Revenue Growth QoQ (YoY)64.16%
P/E Normalized (Annual)40.22x
ROA (Last FY)14.88%
Revenue Growth TTM (YoY)80.59%
EBITD / Share (TTM)$19.47
ROE (5Y Avg)-3.15%
Operating Margin (TTM)42.82%
Cash Flow / Share (Annual)$9.27
P/B Ratio7.10x
P/B Ratio (Quarterly)6.91x
Net Income / Employee (Annual)$808,000
EV / Revenue (TTM)21.72x
Net Interest Coverage (TTM)-81.88x
ROA (TTM)19.39%
EPS Growth QoQ (YoY)113.71%
EV / EBITDA (TTM)37.87x
EPS Incl Extra (Annual)$19.57
Current Ratio (Annual)5.23x
Quick Ratio (Quarterly)4.62x
3-Month Avg Trading Volume0.10M
52-Week Price Return51.26%
EV / Free Cash Flow (Annual)84.62x
P/E Incl Extra (TTM)23.12x
Revenue / Employee (TTM)$2,913,900
Tangible BV / Share (Quarterly)$113.94
P/S Ratio (Annual)12.52x
Asset Turnover (Annual)0.48x
52-Week High$810.00
Operating Margin (5Y Avg)-51.15%
EPS Excl Extra (Annual)$19.57
CapEx CAGR (5Y)85.11%
Tangible BV CAGR (5Y)36.16%
26-Week Price Return-2.10%
Quick Ratio (Annual)4.62x
13-Week Price Return19.24%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)5.23x
Enterprise Value$48.53B
Revenue / Share Growth (5Y)133.37%
Asset Turnover (TTM)0.28x
Book Value / Share Growth (5Y)27.45%
Revenue / Employee (Annual)$2,596,200
Inventory Turnover (Annual)1.02x
Pretax Margin (Annual)30.80%
Cash / Share (Annual)$71.75
3-Month Return Std Dev30.27%
Net Income / Employee (TTM)$1,405,700
ROE (Last FY)17.64%
Net Interest Coverage (Annual)5.58x
EPS Basic Excl Extra (Annual)$19.57
P/FCF (TTM)90.62x
Receivables Turnover (TTM)3.60x
EV / Free Cash Flow (TTM)84.62x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$34.00
Receivables Turnover (Annual)3.60x
ROI (TTM)22.76%
P/S Ratio (TTM)11.15x
Pretax Margin (5Y Avg)-49.62%
Revenue / Share (Annual)$62.87
Tangible BV / Share (Annual)$113.94
Forward P/E27.83x
Price vs S&P 500 (52W)26.90%
P/E Ratio (TTM)23.12x
EPS Growth TTM (YoY)111.42%
Year-to-Date Return6.86%
5-Day Price Return6.69%
EPS Normalized (Annual)$19.57
ROA (5Y Avg)-3.03%
Net Profit Margin (Annual)31.12%
Month-to-Date Return7.04%
EBITD / Share (Annual)$16.26
Operating Margin (Annual)25.38%
LT Debt / Equity (Annual)0.32x
P/CF (TTM)75.85x
ROI (5Y Avg)-3.15%
P/E Excl Extra (TTM)23.12x
EPS Basic Excl Extra (TTM)$34.00
P/TBV (Quarterly)7.17x
P/B Ratio (Annual)6.91x
Inventory Turnover (TTM)1.71x
Pretax Margin (TTM)51.03%
Book Value / Share (Annual)$118.34
Price vs S&P 500 (13W)10.99%
Beta1.02x
P/FCF (Annual)90.62x
Revenue / Share (TTM)$70.22
ROE (TTM)22.91%
52-Week Low$456.60
vGradeD
gGradeA
mGradeB
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.20
4.24
4.24
4.24
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $71.53 |
About
Argenx is a Dutch biopharmaceutical company developing antibody-based therapies for rare autoimmune and immune-mediated diseases. Its lead product, Vyvgart (efgartigimod), is FDA-approved for generalized myasthenia gravis, with the subcutaneous formulation Vyvgart Hytrulo also approved for chronic inflammatory demyelinating polyneuropathy. The company's pipeline includes candidates for primary immune thrombocytopenia, thyroid eye disease, and Sjögren's disease.